Central nervous system histoplasmosis

Current Treatment Options in Neurology

Volumn 10, Issue 3, 2008, Pages 161-167

  Saccente, Michael ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTACID AGENT; CISAPRIDE; CONTRAST MEDIUM; CYCLOSPORIN; DOFETILIDE; FLUCONAZOLE; FUNGUS ANTIGEN; HISTAMINE H2 RECEPTOR ANTAGONIST; ITRACONAZOLE; LEVACETYLMETHADOL; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOBARBITAL; PHENYTOIN; PIMOZIDE; PROTON PUMP INHIBITOR; QUINIDINE; RIFAMPICIN; RITONAVIR; TACROLIMUS;

ANTIFUNGAL ACTIVITY; ANTIGEN DETECTION; ASSISTIVE TECHNOLOGY DEVICE; BEVERAGE; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID ANALYSIS; CEREBROVASCULAR ACCIDENT; CHILL; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG METABOLISM; DYSPNEA; EDEMA; EMBOLISM; ENCEPHALITIS; FOOD; FUNGUS CULTURE; GASTROINTESTINAL TOXICITY; GLOMERULUS FILTRATION RATE; GOLD STANDARD; HEART ARREST; HEART VENTRICLE TACHYCARDIA; HISTOPLASMOSIS; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; KIDNEY TUBULE ACIDOSIS; LIFESTYLE MODIFICATION; LIVER TOXICITY; MENINGITIS; NAUSEA AND VOMITING; NEPHROTOXICITY; PHYSIOTHERAPY; PROGRESSIVE DISSEMINATED HISTOPLASMOSIS; QT PROLONGATION; REVIEW; SIDE EFFECT; SPINAL CORD LESION; STOMACH PH; SUDDEN DEATH; THORAX PAIN; TORSADE DES POINTES; TREATMENT DURATION;

EID: 56349101762     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-008-0017-x     Document Type: Review

References (27)

1. Bradsher RW: Histoplasmosis and blastomycosis. Clin Infect Dis 1996, 22(Suppl 2):S102-S111.
2. Medoff G, Kobayashi GS, Painter A, Travis S: Morphogenesis and pathogenicity of Histoplasma capsulatum. Infect Immun 1987, 55:1355-1358.
3. Wheat LJ, Connolly-Stringfield PA, Baker RL, et al.: Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine (Baltimore) 1990, 69:361-374.
4. Anaissie E, Fainstein V, Samo T, et al.: Central nervous system histoplasmosis: an unappreciated complication of the acquired immunodeficiency syndrome. Am J Med 1988, 84:215-217.
5. Wheat LJ, Batteiger BE, Sathapatayavongs B: Histoplasma capsulatum infections of the central nervous system: a clinical review. Medicine (Baltimore) 1990, 69:244-260.
6. Lee J-H, Slifman NR, Gershon SK, et al.: Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept. Arthritis Rheum 2002, 46:2565-2570.
7. Wheat LJ: Histoplasmosis: experience during outbreaks in Indianapolis and review of the literature. Medicine (Baltimore) 1997, 76:339-354.
8. Sarosi GA, Johnson PC: Disseminated histoplasmosis in patients with human immunodeficiency virus. Clin Infect Dis 1992, 14(Suppl 1):S60-S67.
9. Wheat LJ, Slama TG, Zeckel ML: Histoplasmosis in the acquired immune deficiency syndrome. Am J Med 1985, 78:203-210.
10. Wheat LJ, Musial CE, Jenny-Avital E: Diagnosis and management of central nervous system histoplasmosis. Clin Infect Dis 2005, 40:844-852.
11. Wheat LJ, Kohler RB, Tewari RP. Diagnosis of disseminated histoplasmosis by detection of Histoplasma capsulatum antigen in serum and urine specimens. N Engl J Med 1986, 314:83-88.
12. Wheat LJ, Freifeld AG, Kleiman MB, et al.: Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007, 45:807-825.
13. Wheat J, Hafner R, Wulfsohn M, et al.: Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1993, 118:610-616.
14. Goldman M, Zackin R, Fichtenbaum CJ, et al.: Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clin Infect Dis 2004, 38:1485-1489.
15. Johnson PC, Wheat LJ, Cloud GA, et al.: Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 2002, 137:105-109.
16. Groll AH, Giri N, Petraitis V, et al.: Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000, 182:274-282.
17. Saccente M, McDonnell RW, Baddour LM, et al.: Cerebral histoplasmosis in the azole era: report of four cases and review. South Med J 2003, 96:410-416.
18. Dismukes WE: Introduction to antifungal drugs. Clin Infect Dis 2000, 30:653-657.
19. Ashley ESD, Lewis R, Lewis JS, et al.: Pharmacology of systemic antifungal agents. Clin Infect Dis 2006, 43:S28-S39.
20. Branch RA: Prevention of amphotericin B-induced renal impairment: a review on the use of sodium supplementation. Arch Intern Med 1988, 148:2389-2394.
21. Goodwin SD, Cleary JD, Walawonder CA, et al.: Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis 1995, 20:755-761.
22. Wheat J, Hafner R, Korzun AH, et al.: Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Med 1995, 98:336-342.
23. Wheat J, MaWhinney S, Hafner R, et al.: Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. Am J Med 1997, 103:223-232.
24. Haynes RR, Connolly PA, Durkin MM, et al.: Antifungal therapy for central nervous system histoplasmosis, using a newly developed intracranial model of infection. J Infect Dis 2002, 185:1830-1832.
25. Como JA, Dismukes WE: Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994, 330:263-271.
26. Piscitelli SC, Gallicano KD: Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001, 344:984-996.
27. Odio CM, Navarrete M, Carrillo JM, et al.: Disseminated histoplasmosis in infants. Pediatr Infect Dis 1999, 18:1065-1068.